XASX
DTZ
Market cap11mUSD
Oct 09, Last price
0.02AUD
1D
0.00%
1Q
-16.00%
Jan 2017
-93.23%
IPO
-100.00%
Name
Dotz Nano Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dotz Nano Limited is dedicated to creating and commercializing advanced carbon-based materials that provide crucial solutions for tracing products, preventing counterfeiting, and addressing product liability. The company offers a suite of proprietary technologies, including ValiDotz, BioDotz, Fluorensic, and InSpec, which find application across numerous sectors. These range from enhancing brand security and safeguarding reputation to specialized uses in the oil and gas industry, tagging liquids, lubricants, and polymers, as well as in bio-imaging. Dotz Nano distributes its offerings globally, utilizing a network of partners in regions such as North America, Europe, Japan, China, and Australia. The company also fosters scientific alliances with various academic institutions and has a significant collaboration with Theracell Labs Ltd for the co-development, supply, and licensing of disposable bioprocessing consumables. Dotz Nano Limited's headquarters are located in Kfar Saba, Israel.
Key people
Bernard Brookes
Non-Executive Chairman of the Board · since 2020
Eran Gilboa
Chief Financial Officer · since 2016
Tomer Segev
Chief Financial Officer · since 2019
Michael Shtein
Chief Technology Officer · since 2016
Uzi Breier
Chief Executive Officer, Executive Director · since 2018
Ian Pamensky
Company Secretary · since 2018
Doron Eldar
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2018
Headquarters & legal address
CSBC, Level 14, 330 Collins Street
Melbourne, VIC 3000
AU
Melbourne, VIC 3000
AU
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||